---
figid: PMC3513309__pone.0050221.g004
figtitle: Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell
  Carcinoma Patients Treated with IL-2, InterferonA and Dendritic Cell Vaccine
organisms:
- NA
pmcid: PMC3513309
filename: pone.0050221.g004.jpg
figlink: /pmc/articles/PMC3513309/figure/pone-0050221-g004/
number: F4
caption: Immune therapy leads to activation of stimulatory pathways in responding
  subjects. Examples of activated pathways are shown. The CD28 co-stimulatory, nuclear
  factor of activated T-cell (NFAT) and HIFα pathways were relatively up-regulated
  () for responding subjects. Another key pathway (IPA) differentially regulated in
  R vs. NR PBLs was the Flt3 signaling pathway (fms-like tyrosine kinase receptor-3;
  CD135) in which genes were overall down-regulated in non-responding patients but
  up-regulated in responding patients (). To determine whether the genes picked by
  ingenuity software are able to discriminate between responding and non-responding
  patients, we performed supervised (selected genes) clustering analysis of genes
  important for Flt3 signaling. This clearly grouped responders and non-responders
  in 2 distinct groups (), strengthening the IPA-result. Supervised clusters of pathways
  in 4A–4C led to similar results (data not shown).
papertitle: Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell
  Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine.
reftext: Benita Wolf, et al. PLoS One. 2012;7(12):e50221.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6481029
figid_alias: PMC3513309__F4
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC3513309__F4
ndex: 8b0651cc-de92-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3513309__pone.0050221.g004.html
  '@type': Dataset
  description: Immune therapy leads to activation of stimulatory pathways in responding
    subjects. Examples of activated pathways are shown. The CD28 co-stimulatory, nuclear
    factor of activated T-cell (NFAT) and HIFα pathways were relatively up-regulated
    () for responding subjects. Another key pathway (IPA) differentially regulated
    in R vs. NR PBLs was the Flt3 signaling pathway (fms-like tyrosine kinase receptor-3;
    CD135) in which genes were overall down-regulated in non-responding patients but
    up-regulated in responding patients (). To determine whether the genes picked
    by ingenuity software are able to discriminate between responding and non-responding
    patients, we performed supervised (selected genes) clustering analysis of genes
    important for Flt3 signaling. This clearly grouped responders and non-responders
    in 2 distinct groups (), strengthening the IPA-result. Supervised clusters of
    pathways in 4A–4C led to similar results (data not shown).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD28
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - CD80
  - CD86
  - CD4
  - CD40
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - CTLA4
  - CD247
  - CD3D
  - CD3E
  - CD3G
  - GRAP2
  - SYK
  - WAS
  - TK1
  - TK2
  - ZAP70
  - BCR
  - RN7SL263P
  - CDC42
  - AKT1
  - RAC1
  - RAC2
  - RAC3
  - RHOG
  - NR0B2
  - BTK
  - XYLT2
  - SOS1
  - SOS2
  - PLCG1
  - PLCG2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - CSK
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - CALM2
  - CALM3
  - PICALM
  - SNAP91
  - CALM1
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - MAP2K1
  - PDK1
  - PDPK1
  - MAP3K1
  - ITPR1
  - ITPR3
  - PRKCE
  - MAPK3
  - MAPK1
  - CSNK1A1
  - KRT1
  - CSNK1A1L
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - AKT2
  - AKT3
  - GATA4
  - MEF2A
  - MYEF2
  - MEF2C
  - MEF2D
  - MEF2B
  - JUN
  - TAC3
  - MAPK8
  - MAPK9
  - MAPK10
  - IL2
  - HIF1A
  - EPAS1
  - HIF3A
  - FLT3LG
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - FLT3
  - SLC2A1
  - GRB2
  - MDM2
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - INPP5D
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - GAB2
  - PTPN11
  - NOS1
  - NOS2
  - NOS3
  - HSP90AA1
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - EDN1
  - EPO
  - TIMP1
  - EPX
  - MTOR
  - LDHA
  - LDHB
  - LDHC
  - EIF4EBP1
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - RPS6KB1
  - RPS6KB2
  - RBX1
  - EIF4E
  - EIF4E2
  - EIF4E3
  - EP300
  - CREBBP
  - OPN1LW
  - PAG1
  - PCBP4
  - ARNT
  - MIA3
  - APEX1
  - TEAD1
  - TFPI2
  - CUL2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - ELK1
  - KCNH4
  - KCNH8
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - BAD
  - EPHB2
  - MAP2K2
  - CRK
  - AIMP2
  - AHSA1
  - POLDIP2
  - Cancer
  - Noonan syndrome
  - Rheumatoid arthritis
---
